ClinicalTrials.gg
CompletedNCT02675023Updated Oct 15, 2019

Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects

A Phase 1 interventional study of M923 in Healthy, sponsored by Momenta Pharmaceuticals, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-15.

Sponsored by Momenta Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
603
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will assess the pharmacokinetic (PK) and safety of a single 0.8 mL (40 mg) subcutaneous (SC) dose of M923 administered via an auto-injector (AI) or a prefilled syringe (PFS) in healthy subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Momenta Pharmaceuticals, Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.

First submitted before Momenta Pharmaceuticals, Inc. became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female participants aged 18 to 55 years, inclusive
  2. Healthy participants as determined by pre-study medical history, physical examination, vital signs and 12-lead (ECG)
  3. Participants with clinical laboratory test results that are not and are acceptable to the investigator at screening and admission to the study site (Day -1)
  4. Participants with a body weight between 60.0 kg and 100.0 kg and a between 18.5 kg/m2 and 34.9 kg/m2, inclusive
  5. Healthy male participants must be willing to comply with the restrictions for this study.

    -Male participants with non-pregnant female partners of should avoid conception of a child during the study (up to Day 71 post-dose) and for 90 days thereafter.

  6. Healthy female participants must have a negative pregnancy test at screening and on admission to the study site (Day -1), must not be lactating and must be using an acceptable method of contraception throughout the study and for 30 days after study completion, or be of non-childbearing potential.

    -Non-pregnant female partners of male participants who are of childbearing potential should use an effective form of contraception.

  7. Participants who have smoked ≤10 cigarettes or 3 cigars or 3 pipes/day for at least 3 months prior to screening and are willing to comply with smoking restrictions during residency at the study site
  8. Participants who are able to understand and provide written including signature on an informed consent form (ICF) approved by an Ethics Committee (EC)/ Institutional Review Board (IRB)
  9. Participants who have provided written authorization for use and disclosure of protected health information
  10. Participants who agree to abide by the study schedule and dietary restrictions and to return for the required assessments

Exclusion criteria

Exclusion Criteria:

  1. History and/or current presence of angioedema, or eczematous dermatitis that requires prescription medication, clinically significant , or severe allergic reactions (either spontaneous or following IP administration), also including known or suspected clinically relevant drug hypersensitivity to any components of the IP or comparable drugs, including latex
  2. Active or latent tuberculosis or who have a history of TB.
  3. History of invasive and/or active systemic fungal infections or other severe opportunistic infections, including recurrent or clinically significant chronic local fungal infections
  4. A serious infection within 6 months prior to product (IP) administration and/or an infection within 2 weeks of screening or during the screening period unless resolved completely within 2 weeks of admission to the study site on Day -1
  5. Herpes zoster infection in the last year or more than 2 herpes zoster infections in his/her lifetime
  6. Frequent chronic or recurrent infections (defined as >3 a year requiring prescribed treatment)
  7. Previous use of adalimumab, HUMIRA®, or another recombinant human monoclonal antibody
  8. Intake of any investigational drug in another study within 30 days (or 5 half-lives, whichever is greater) prior to intake of IP in this study or have received the last dose of a study drug more than 30 days ago (or 5 half-lives, whichever is greater) but who are on extended follow-up, or planned intake of an investigational drug (other than for this study) during the course of this study
  9. History of alcohol abuse in the year preceding the screening visit, or history of excess alcohol consumption.
  10. Known history of opioid or cocaine drug abuse or any other drug abuse in the past year or positive tests for drugs of abuse or alcohol at screening or admission to the study site (Day -1)
  11. Donation of blood or blood products (eg, plasma, ) within 30 days prior to IP administration
  12. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), dietary supplements or herbal medication during the 2 weeks prior to IP administration or longer if the medication has a long half-life. Use of any medication deemed necessary by the participant's physician to treat or prevent any medical condition, paracetamol/acetaminophen ≤3 g/day and use of vitamins at daily recommended doses is allowed; for female volunteers, oral and hormone replacement therapy is allowed
  13. History of or existing congestive heart failure
  14. History of or existing signs or symptoms of demyelinating disease such as optic neuritis and/or multiple sclerosis
  15. History of any cancer including lymphoma, leukemia, skin cancer or cervical carcinoma in situ
  16. Impaired liver function
  17. History of immunodeficiency (including those participants with a positive test for [HIV] I and II at screening) or other clinically significant immunological disorders, or auto-immune disorders, (eg, rheumatoid arthritis, lupus erythematosus, scleroderma, psoriasis)
  18. Positive test for anti-citrullinated protein antibodies at screening
  19. Clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological (including pancytopenia, aplastic anemia, or blood dyscrasia), metabolic (including known diabetes mellitus), lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders as judged by the investigator
  20. Received a within 12 weeks prior to admission to the study site (Day -1) or plan to receive a live vaccine during the study (up to and including Day 71)
  21. Volunteers who are vegans or have medical dietary restrictions
  22. Volunteers who cannot communicate reliably with the investigator
  23. Volunteer is a family member or employee of the investigator or study site staff or study team
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
603 participants (actual)

Study arms

  • Experimental
    Auto-injector (AI)

    M923 administered via AI

    Biological: M923

  • Experimental
    Prefilled syringe (PFS)

    M923 administered via PFS

    Biological: M923

Interventions

  • BiologicalM923

    Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)

    Also known as: Adalimumab

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Area under the concentration-time curve from 0 to infinity

    Area under the concentration-time curve in serum from time zero (predose) extrapolated to infinity \[AUC(0-inf)\]

    Time frame: Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71

  2. Pharmacokinetics: Area under the concentration-time curve from 0 to 336 hours

    Area under the concentration-time curve in serum from time zero (predose) to 336 hours postdose \[AUC(0-336)\]

    Time frame: Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, and 15

  3. Pharmacokinetics: Maximum concentration in serum (Cmax)

    Time frame: Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71

Secondary outcomes

  1. Pharmacokinetics: Serum M923 concentration up to Day 71

    Time frame: Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71

  2. Pharmacokinetics: Area under the concentration-time curve in serum from time zero (predose) to 1200 hours postdose [AUC(0-1200)]

    Time frame: Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, and 50

  3. Pharmacokinetics: Area under the concentration-time curve in serum from time zero (predose) to time of the last quantifiable concentration [AUC(0-last)]

    Time frame: Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71

  4. Pharmacokinetics: Time of maximum concentration in serum [tmax]

    Obtained directly from the observed concentration versus time data

    Time frame: Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71

  5. Pharmacokinetics: Terminal rate constant (λ z)

    Time frame: Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71

  6. Pharmacokinetics: Terminal half-life (t½)

    Time frame: Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71

  7. Pharmacokinetics: Apparent volume of distribution (Vz/F)

    Time frame: Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71

  8. Pharmacokinetics: Apparent systemic clearance after extravascular dosing (CL/F)

    Time frame: Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71

  9. Pharmacokinetics: Area under the concentration-time curve extrapolated from time "t" to infinity [% AUCex]

    Time frame: Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71

  10. Pharmacokinetics: Area under the serum concentration-time curves from time zero (predose) to time "t" [AUC(0-t)] by which >20.0% of participants have developed neutralizing antidrug antibody [nADA]

    Time frame: Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71

  11. Non-serious and serious adverse events (SAEs)

    Time frame: Throughout the study period of approximately 8 months

  12. Incidence of injection site reactions

    Time frame: Throughout the study period of approximately 8 months

  13. Clinically significant changes in Vital signs

    Time frame: Throughout the study period of approximately 8 months

  14. Number of participants with new clinically significant findings from the physical examination

    Physical examination will be done on the following body systems: general appearance, head and neck, eyes and ears, nose and throat, chest, lungs, heart, abdomen, extremities and joints, lymph nodes, skin, and neurological.

    Time frame: Throughout the study period of approximately 8 months

  15. Clinically significant changes in Twelve-lead electrocardiogram (ECG)

    Time frame: Throughout the study period of approximately 8 months

  16. Clinically significant changes in laboratory results

    Time frame: Throughout the study period of approximately 8 months

  17. Clinically significant changes in clinical chemistry

    Time frame: Throughout the study period of approximately 8 months

  18. Clinically significant changes in urinalysis

    Time frame: Throughout the study period of approximately 8 months

07

Study locations

2 sites
  • QOPK Phase 1 Clinic
    Overland Park, Kansas 66211, United States
  • QLON Phase 1 Clinic
    London, SE1 1YR, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2016
First posted
Feb 5, 2016
Start
Jan 2016
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Last update
Oct 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02675023
Responsible party
Sponsor
First posted
Feb 5, 2016
Start date
Jan 2016
Primary completion
Jul 2016
Completion
Jul 2016
Last update
Oct 15, 2019

Study contacts

John Caminis, MD
study director · Shire
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion